Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug

Ipsen (EPA:IPN) said today that Teijin Pharma Ltd. won approval from the Japanese Ministry of Health, Labor and Welfare for Ipsen’s Somatuline as a therapy for gastroenteropancreatic neuroendocrine tumors.
The subcutaneous drug was approved in Japan in 2012 for the treatment of acromegaly and pituitary gigantism.
Get the full story at our sister site, Drug Delivery Business News.
The post Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug appeared first on MassDevice.

Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat Ipsen Teijin Pharma Source Type: news